Chemistry:Iscartrelvir
From HandWiki
Iscartrelvir is an investigational new drug developed by the Westlake University for the treatment of COVID-19. It targets the SARS-CoV-2 3CL protease, which is crucial for the replication of the virus responsible for COVID-19.[1][2]
See also
- 3CLpro-1
- Rupintrivir
References
- ↑ "Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China". European Journal of Medicinal Chemistry 257. September 2023. doi:10.1016/j.ejmech.2023.115503. PMID 37229831.
- ↑ "Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro". ACS Central Science 9 (2): 217–227. February 2023. doi:10.1021/acscentsci.2c01359. PMID 36844503.
 |  |
